MSANTD2-AS1 and urinary bladder carcinoma: After overexpression of MSANTD2 or lncRNA BCLET, we found that the malignant phenotype of bladder cancer cells was suppressed and tumor growth was inhibited in vivo, suggesting that MSANTD2 and lncRNA BCLET may act as tumor suppressors in bladder cancer and may be used as a therapeutic target in the future.